EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC

Eftychia Kiousi, Vasiliki Lyraraki, Georgia Lamprini Mardiki, Nikolina Stachika, Aikaterini Konstantina Damianou, Christina Panagiotis Malainou, Nikolaos Syrigos, Georgia Gomatou iD, Elias Kotteas iD

Cancers · 26.11.2023 · 15 (23) · 5589

DOI: 10.3390/cancers15235589 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.11.2023. Verfasst von Eftychia Kiousi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Third Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of immune checkpoint inhibitors in the therapeutics of non-small cell lung cancer (NSCLC) has been a game-changer in the management of patients with lung cancer; however, challenges do exist since a non-negligible subset of patients does not respond to therapy. Various immunotherapeutic anticancer strategies have been increasingly developed in recent years, including monoclonal antibodies, adoptive T-cell therapy, and vaccines. Fueled by their rapid drug development and successful implementation during the COVID-19 pandemic, messenger RNA (mRNA) vaccines represent an emerging therapeutic approach in other fields of medicine, including oncology. Several clinical trials are currently being conducted to assess the safety and efficacy of mRNA vaccines regarding a variety of solid tumors. Combining mRNA vaccines with other immunotherapeutic approaches has also been suggested and is currently under investigation. Although, in the case of NSCLC, the investigation is still in its early stages, the initial results raise the need for clinician awareness of these promising therapies. To this end, in the present review, we aim to summarize current advances in the development of mRNA vaccines in NSCLC therapeutics and discuss pragmatic challenges regarding their drug development and the different opportunities for implementation.

Schlagwörter

Stichwörter der Autor:innen

NSCLCanticancer vaccineslung cancermRNA vaccinesmessenger RNA

Autor:innen und Institutionen

  • Oncology Unit, Third Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Georgia Gomatou, Elias Kotteas

Zitieren

APA

Kiousi, E., Lyraraki, V., Mardiki, G. L., Stachika, N., Damianou, A. K., Malainou, C. P., Syrigos, N., Gomatou, G., & Kotteas, E. (2023). Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC. Cancers, 15(23), 5589. https://doi.org/10.3390/cancers15235589

Vancouver

Kiousi E, Lyraraki V, Mardiki GL, Stachika N, Damianou AK, Malainou CP, et al. Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC. Cancers. 2023;15(23):5589. doi:10.3390/cancers15235589

BibTeX
@article{Kiousi2023,
  author = {Kiousi, Eftychia and Lyraraki, Vasiliki and Mardiki, Georgia Lamprini and Stachika, Nikolina and Damianou, Aikaterini Konstantina and Malainou, Christina Panagiotis and Syrigos, Nikolaos and Gomatou, Georgia and Kotteas, Elias},
  title = {Progress and Challenges of Messenger RNA Vaccines in the Therapeutics of NSCLC},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {23},
  pages = {5589},
  doi = {10.3390/cancers15235589}
}
Kostenlos starten →